EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Soluble Thrombomodulin Links Viremia and Mortality During COVID‐19: Results From the ACTIV‐4a Trial

Benjamin E Zuchelkowski iD, Kyle W Inman iD, S Mehdi Nouraie iD, Neeharika Beru, Asma Naqvi iD, Shulin Qin, Calvin H Yeh, Yingze Zhang iD, Faraaz A Shah iD, Lokesh Sharma iD, Charles S Dela Cruz, Lianghui Zhang iD und 10 weitere

Journal of the American Heart Association · 2026

DOI: 10.1161/jaha.125.047693 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Heart Association, 2026. Verfasst von Benjamin E Zuchelkowski und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine University of Pittsburgh School of Medicine Pittsburgh PA USA. Hauptthemen laut MEDLINE: COVID-19, Thrombomodulin, Thrombosis, Viremia. Die Arbeit nennt 41 Literaturangaben. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

COVID‐19 and other respiratory viral infections can cause cardiovascular complications. SARS‐CoV‐2 virions are found in the blood, and circulating viral RNA levels are associated with death. We hypothesized that viremia can induce thrombotic endotheliopathy that contributes to death and studied this relationship in patients hospitalized for COVID‐19 and enrolled in the ACTIV‐4a (Accelerating COVID‐19 Therapeutic Interventions and Vaccines) randomized trial of antithrombotic therapy.

Methods

We quantified SARS‐CoV‐2 nucleocapsid RNA and protein in plasma and measured their associations with clinical outcomes and biomarkers of thromboinflammation and endotheliopathy. We used Cox regression and Fine–Gray competing risk models to analyze survival and thrombosis. We conducted causal mediation analysis to explore whether thrombotic endotheliopathy mediates the relationship between viral RNA and death.

Results

In 93 patients, SARS‐CoV‐2 RNA and N‐antigen were higher in nonsurvivors. Baseline viral RNA levels were associated with increased 90‐day death (hazard ratio [HR], 1.31 [95% CI, 1.17–1.46]) and thrombosis (HR, 1.35 [95% CI, 1.24–1.47]). Viral RNA more effectively predicted survivorship than N‐antigen levels. Soluble thrombomodulin, a biomarker of thrombotic endotheliopathy, positively correlated with viral RNA levels. Mediation analysis revealed that soluble thrombomodulin accounts for 12.2% (95% CI, 0.1%–32.3%; P =0.048) after adjustment for age and sex of the relationship between viral RNA and the 90‐day mortality rate.

Conclusions

Elevated plasma SARS‐CoV‐2 RNA levels are associated with death in ACTIV‐4a, which is causally mediated in part by soluble thrombomodulin. We propose that lung–blood viral dissemination is a potential mechanism for cardiovascular complications of respiratory viruses. Registration URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT04505774.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19ThrombomodulinThrombosisViremiaAgedFemaleHumansMaleMiddle AgedBiomarkersRisk FactorsRNA, ViralSARS-CoV-2

Stichwörter der Autor:innen

SARS‐CoV‐2endotheliopathymediation analysisthrombosisviremia

Substanzen

BiomarkersRNA, ViralTHBD protein, humanThrombomodulin

Autor:innen und Institutionen

  • Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine University of Pittsburgh School of Medicine Pittsburgh PA USA.
  • Division of Infectious Diseases University of Pittsburgh School of Medicine Pittsburgh PA USA.
  • Thrombosis and Atherosclerosis Research Institute and McMaster University Hamilton Ontario Canada.
  • Veterans Affairs Pittsburgh Healthcare System Pittsburgh PA USA.
  • Department of Medicine Rutgers, Robert Wood Johnson Medical School New Brunswick NJ USA.
  • Trauma and Transfusion Medicine Research Center, Department of Surgery University of Pittsburgh School of Medicine Pittsburgh PA USA.

ORCID-Profile: Benjamin E Zuchelkowski, Kyle W Inman, S Mehdi Nouraie, Asma Naqvi, Yingze Zhang, Faraaz A Shah, Lokesh Sharma, Lianghui Zhang, Bryan J McVerry, Alison Morris, Matthew D Neal, Jansen Seheult, Georgios D Kitsios, John W Mellors, Daniel A Lawrence, Paul Y Kim, Jana L Jacobs, William G Bain

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Zuchelkowski, B. E., Inman, K. W., Nouraie, S. M., Beru, N., Naqvi, A., Qin, S., Yeh, C. H., Zhang, Y., Shah, F. A., Sharma, L., Dela Cruz, C. S., Zhang, L., McVerry, B. J., Morris, A., Neal, M. D., Seheult, J., Kitsios, G. D., Mellors, J. W., Lawrence, D. A., …, & Bain, W. G. (2026). Soluble Thrombomodulin Links Viremia and Mortality During COVID‐19: Results From the ACTIV‐4a Trial. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.047693

Vancouver

Zuchelkowski BE, Inman KW, Nouraie SM, Beru N, Naqvi A, Qin S, et al. Soluble Thrombomodulin Links Viremia and Mortality During COVID‐19: Results From the ACTIV‐4a Trial. Journal of the American Heart Association. 2026. doi:10.1161/jaha.125.047693

BibTeX
@article{Zuchelkowski2026,
  author = {Zuchelkowski, Benjamin E and Inman, Kyle W and Nouraie, S Mehdi and Beru, Neeharika and Naqvi, Asma and Qin, Shulin and Yeh, Calvin H and Zhang, Yingze and Shah, Faraaz A and Sharma, Lokesh and Dela Cruz, Charles S and Zhang, Lianghui and McVerry, Bryan J and Morris, Alison and Neal, Matthew D and Seheult, Jansen and Kitsios, Georgios D and Mellors, John W and Lawrence, Daniel A and Kim, Paul Y and Jacobs, Jana L and Bain, William G},
  title = {Soluble Thrombomodulin Links Viremia and Mortality During COVID‐19: Results From the ACTIV‐4a Trial},
  journal = {Journal of the American Heart Association},
  year = {2026},
  doi = {10.1161/jaha.125.047693}
}
Kostenlos starten →